Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Langenbeck's Archives of Surgery
Published in: Langenbeck's Archives of Surgery 1/2023

Open Access 01-12-2023 | Obesity | Review Article

Mechanisms linking bariatric surgery to adipose tissue, glucose metabolism, fatty liver disease and gut microbiota

Authors: Saverio Latteri, Maria Sofia, Stefano Puleo, Angelica Di Vincenzo, Saverio Cinti, Sergio Castorina

Published in: Langenbeck's Archives of Surgery | Issue 1/2023

Login to get access

Abstract

Purpose

In the last 20 years, bariatric surgery has achieved an important role in translational and clinical research because of obesity comorbidities. Initially, a tool to lose weight, bariatric surgery now has been shown to be involved in several metabolic pathways.

Methods

We conducted a narrative review discussing the underlying mechanisms that could explain the impact of bariatric surgery and the relationship between obesity and adipose tissue, T2D, gut microbiota, and NAFLD.

Results

Bariatric surgery has an impact in the relation between obesity and type 2 diabetes, but in addition  it induces the white-to-brown adipocyte trans-differentiation, by enhancing thermogenesis. Another issue is the connection of bariatric surgery with the gut microbiota and its role in the complex mechanism underlying weight gain.

Conclusion

Bariatric surgery modifies gut microbiota, and these modifications influence lipid metabolism, leading to improvement of non-alcoholic fatty liver disease.
Literature
1.
NCD Risk Factor Collaboration (NCD-RisC) (2016) Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 192 million participants. Lancet 387:1377–1396
2.
Klöting N, Fasshauer M, Dietrich A, Kovacs P, Schön MR, Kern M, Stumvoll M, Blüher M (2010) Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 299:E506–E515PubMedCrossRef
3.
Kotzbeck P, Giordano A, Mondini E, Murano I, Severi I, Venema W, Cecchini MP, Kershaw EE, Barbatelli G, Haemmerle G, Zechner R, Cinti S (2018) Brown adipose tissue whitening leads to brown adipocyte death and adipose tissue inflammation. J Lipid Res 59:784–794PubMedPubMedCentralCrossRef
4.
Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, Aminian A, Pothier CE, Kim ES, Nissen SE, Kashyap SR (2014) STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 370:2002–2013PubMedPubMedCentralCrossRef
5.
Sinclair P, Brennan DJ, le Roux CW (2018) Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. Nat Rev Gastroenterol Hepatol 15:606–624PubMedCrossRef
6.
7.
Wiggins T, Majid MS, Agrawal S (2020) From the Knife to the Endoscope-a History of Bariatric Surgery. Curr Obes Rep 9:315–325PubMedCrossRef
8.
Angrisani L, Santonicola A, Iovino P, Ramos A, Shikora S, Kow L (2021) Bariatric surgery survey 2018: similarities and disparities among the 5 IFSO chapters. Obes Surg 31:1937–1948PubMedPubMedCentralCrossRef
9.
Phillips BT, Shikora SA (2018) The history of metabolic and bariatric surgery: development of standards for patient safety and efficacy. Metab 79:97–107CrossRef
10.
11.
Hacken B, Rogers A, Chinchilli V, Silvis M, Mosher T, Black K (2019) Improvement in knee osteoarthritis pain and function following bariatric surgery: 5-year follow-up. Surg Obes Relat Dis 15:979–984PubMedCrossRef
12.
Scopinaro N, Gianetta E, Civalleri D, Bonalumi U, Bachi V (1979) Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg 66:618–620PubMedCrossRef
13.
14.
15.
O’Brien PE, MacDonald L, Anderson M, Brennan L, Brown WA (2013) Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg 257:87–94PubMedCrossRef
16.
Regan JP, Inabnet WB, Gagner M, Pomp A (2003) Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg 13:861–864PubMedCrossRef
17.
18.
Rutledge R, Walsh TR (2005) Continued excellent results with the mini-gastric bypass: six-year study in 2,410 patients. Obes Surg 15:1304–1308PubMedCrossRef
19.
Robert M, Espalieu P, Pelascini E, Caiazzo R, Sterkers A, Khamphommala L, Poghosyan T, Chevallier JM, Malherbe V, Chouillard E, Reche F, Torcivia A, Maucort-Boulch D, Bin-Dorel S, Langlois-Jacques C, Delaunay D, Pattou F, Disse E (2019) Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. Lancet 393:1299–1309PubMedCrossRef
20.
Hussain A, Van den Bossche M, Kerrigan DD, Alhamdani A, Parmar C, Javed S, Harper C, Darrien J, Singhal R, Yeluri S, Vasas P, Balchandra S, El-Hasani S (2019) Retrospective cohort study of 925 OAGB procedures. The UK MGB/OAGB collaborative group. Int J Surg 69:13–18PubMedCrossRef
21.
Saunders KH, Igel LI, Saumoy M, Sharaiha RZ, Aronne LJ (2018) Devices and endoscopic bariatric therapies for obesity. Curr Obes Rep 7:162–171PubMedCrossRef
22.
23.
Vitali A, Murano I, Zingaretti MC, Frontini A, Ricquier D, Cinti S (2012) The adipose organ of obesity-prone C57BL/6J mice is composed of mixed white and brown adipocytes. J Lipid Res 53:619–629PubMedPubMedCentralCrossRef
24.
Ronkainen J, Mondini E, Cinti F, Cinti S, Sebért S, Savolainen MJ, Salonurmi T (2016) Fto-deficiency affects the gene and MicroRNA expression involved in brown adipogenesis and browning of white adipose tissue in mice. Int J Mol Sci 17:1851PubMedPubMedCentralCrossRef
25.
Rodriguez A, Catalan V, Gomez-Ambrosi J, Fruhbeck G (2007) Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des 13:2169–2175PubMedCrossRef
26.
Lehr S, Hartwig S, Sell H (2012) Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl 6:91–101PubMedCrossRef
27.
La Cava A, Alviggi C, Matarese G (2004) Unraveling the multiple roles of leptin in inflammation and autoimmunity. J Mol Med 82:4–11PubMedCrossRef
28.
Mohan V, Deepa R, Pradeepa R et al (2005) Association of low adiponectin levels with the metabolic syndrome—the Chennai Urban Rural Epidemiology Study (CURES-4). Metab 54:476–481CrossRef
29.
Thörne A, Lönnqvist F, Apelman J, Hellers G, Arner P (2002) A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 26:193–199PubMedCrossRef
30.
Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697–738PubMedCrossRef
31.
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821–1830PubMedPubMedCentralCrossRef
32.
Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347–2355PubMedCrossRef
33.
Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M, Cinti S (2008) Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 49:1562–1568PubMedCrossRef
34.
Zimmet P, Shaw J (2017) Diabetes: rising incidence of diabetes mellitus in youth in the USA. Nat Rev Endocrinol 13:379–380PubMedCrossRef
35.
Exley MA, Hand L, O’Shea D, Lynch L (2014) Interplay between the immune system and adipose tissue in obesity. J Endocrinol 223:R41–R48PubMedCrossRef
36.
Frikke-Schmidt H, O’Rourke RW, Lumeng CN, Sandoval DA, Seeley RJ (2016) Does bariatric surgery improve adipose tissue function? Obes Rev 17:795–809PubMedPubMedCentralCrossRef
37.
Galanakis CG, Daskalakis M, Manios A, Xyda A, Karantanas AH, Melissas J (2014) Computed tomography-based assessment of abdominal adiposity changes and their impact on metabolic alterations following bariatric surgery. World J Surg 39:417–423CrossRef
38.
Toro-Ramos T, Goodpaster BH, Janumala I et al (2015) Continued loss in visceral and intermuscular adipose tissue in weight-stable women following bariatric surgery. Obes 23:62–69CrossRef
39.
Keidar A, Appelbaum L, Schweiger C et al (2014) Baseline abdominal lipid partitioning is associated with the metabolic response to bariatric surgery. Obes Surg 24:1709–1716PubMedCrossRef
40.
Labrecque J, Laforest S, Michaud A, Biertho L, Tchernof A (2017) Impact of bariatric surgery on white adipose tissue inflammation. Can J Diabetes 41(4):407–417PubMedCrossRef
41.
Faramia J, Ostinelli G, Drolet-Labelle V, Picard F, Tchernof A (2020) Metabolic adaptations after bariatric surgery: adipokines, myokines and hepatokines. Curr Opin Pharmacol 52:67–74PubMedCrossRef
42.
Khosravi-Largani M, Nojomi M, Aghili R et al (2019) Evaluation of all types of metabolic bariatric surgery and its consequences: a systematic review and meta-analysis. OBES SURG 29:651–690PubMedCrossRef
43.
Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H, Kaser S, Kaser A, Tilg H (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59:1259–1264PubMedCrossRef
44.
Xu XJ, Apovian C, Hess D, Carmine B, Saha A, Ruderman N (2015) Improved insulin sensitivity 3 months after RYGB surgery is associated with increased subcutaneous adipose tissue AMPK activity and decreased oxidative stress. Diabetes 64:3155–3159PubMedPubMedCentralCrossRef
45.
Salminen A, Hyttinen JM, Kaarniranta K (2011) AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J Mol Med 89:667–676PubMedCrossRef
46.
Hankir MK, Seyfried F (2020) Do bariatric surgeries enhance brown/beige adipose tissue thermogenesis? Front Endocrinol 30(11):275CrossRef
47.
Dadson P, Hannukainen JC, Din MU, Lahesmaa M, Kalliokoski KK, Iozzo P et al (2018) Brown adipose tissue lipid metabolism in morbid obesity: effect of bariatric surgery-induced weight loss. Diabetes Obes Metab 20:1280–1288PubMedCrossRef
48.
Vijgen GH, Bouvy ND, Teule GJ et al (2012) Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 97(7):E1229–E1233PubMedCrossRef
49.
Krieger JP, Santos da Conceicao EP, Sanchez-Watts G et al (2018) Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats. Am J Physiol Regul Integr Comp Physiol. 315(4):708–20CrossRef
50.
Chen Y, Yang J, Nie X et al (2018) Effects of bariatric surgery on change of Brown adipocyte tissue and energy metabolism in obese mice. Obes Surg 28(3):820–830PubMedCrossRef
51.
Hui SCN, Wong SKH, Ai Q et al (2019) Observed changes in brown, white, hepatic and pancreatic fat after bariatric surgery: evaluation with MRI. Eur Radiol 29(2):849–856PubMedCrossRef
52.
Piquer-Garcia I, Cereijo R, Corral-Perez J, Pellitero S, Martinez E, Taxeras SD et al (2020) Use of infrared thermography to estimate brown fat activation after a cooling protocol in patients with severe obesity that underwent bariatricsurgery. Obes Surg 30(6):2375–2381PubMedCrossRef
53.
Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439(7075):484–489PubMedCrossRef
54.
Villarroya F, Vidal-Puig A (2013) Beyond the sympathetic tone: the new brown fat activators. Cell Metab 17(5):638–643PubMedCrossRef
55.
Boles A, Kandimalla R, Reddy PH (2017) Dynamics of diabetes and obesity: Epidemiological perspective. Biochim Biophys Acta Mol Basis Dis 1863:1026–1036PubMedCrossRef
56.
Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:4–14PubMedCrossRef
57.
Giannulis I, Mondini E, Cinti F, Frontini A, Murano I, Barazzoni R, Barbatelli G, Accili D, Cinti S (2014) Increased density of inhibitory noradrenergic parenchymal nerve fibers in hypertrophic islets of Langerhans of obese mice. Nutr Metab Cardiovasc Dis 24:384–392PubMedCrossRef
58.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808PubMedPubMedCentralCrossRef
59.
Hotamisligil GS (2017) Inflammation, metaflammation and immunometabolic disorders. Nature 542:177–185PubMedCrossRef
60.
Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, Seo JB, Ofrecio JM, Wollam J, Hernandez-Carretero A, Fu W, Li P, Olefsky JM (2017) Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 171:372-384.e12PubMedCrossRef
61.
Nigi L, Grieco GE, Ventriglia G, Brusco N, Mancarella F, Formichi C, Dotta F, Sebastiani G (2018) MicroRNAs as regulators of insulin signaling: research updates and potential therapeutic perspectives in type 2 diabetes. Int J Mol Sci 19(12):3705PubMedPubMedCentralCrossRef
62.
Ferrannini E (1997) Insulin resistance is central to the burden of diabetes. Diabetes Metab Rev 13:81–86PubMedCrossRef
63.
Kitamura Y, Accili D (2004) New insights into the integrated physiology of insulin action. Rev Endocr Metab Disord 5:143–149PubMedCrossRef
64.
Xuan S, Szabolcs M, Cinti F, Perincheri S, Accili D, Efstratiadis A (2010) Genetic analysis of type-1 insulin-like growth factor receptor signaling through insulin receptor substrate-1 and -2 in pancreatic beta cells. J Biol Chem 285:41044–41050PubMedPubMedCentralCrossRef
65.
Cinti F, Bouchi R, Kim-Muller JY, Ohmura Y, Sandoval PR, Masini M, Marselli L, Suleiman M, Ratner LE, Marchetti P, Accili D (2016) Evidence of β-cell dedifferentiation in human type 2 diabetes. J Clin Endocrinol Metab 101:1044–1054PubMedCrossRef
66.
Lin EE, Scott-Solomon E, Kuruvilla R (2021) Peripheral innervation in the regulation of glucose homeostasis. Trends Neurosci 44:189–202PubMedCrossRef
67.
Pareek M, Schauer PR, Kaplan LM, Leiter LA, Rubino F, Bhatt DL (2018) Metabolic surgery: weight loss, diabetes, and beyond. J Am Coll Cardiol 71:670–687PubMedCrossRef
68.
Bose M, Teixeira J, Olivan B, Bawa B, Arias S, Machineni S, Pi-Sunyer FX, Scherer PE, Laferrère B (2010) Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes 2:47–55PubMedCrossRef
69.
Sheng B, Truong K, Spitler H, Zhang L, Tong X, Chen L (2017) The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes Surg 27:2724–2732PubMedCrossRef
70.
Liang H, Cao Q, Liu H, Guan W, Wong C, Tong D (2018) The predictive factors for diabetic remission in Chinese patients with BMI > 30 kg/m2 and BMI < 30 kg/m2 are different. Obes Surg 28:1943–1949PubMedCrossRef
71.
Park MY, Kim SJ, Ko EK, Ahn SH, Seo H, Sung MK (2016) Gut microbiota- associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice. J Appl Microbiol 121:800–810PubMedCrossRef
72.
Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, Chen T, Qu C, Rajani C, Dong B, Li D, Jia W (2017) Bile acid is a significant host factor shaping the gut microbiome of diet- induced obese mice. BMC Biol 15:120PubMedPubMedCentralCrossRef
73.
Sanmiguel C, Gupta A, Mayer EA (2015) Gut microbiome and obesity: a plausible explanation for obesity Curr Obes Rep 4:250–261PubMed
74.
Portune KJ, Benìtez-Pàez A, Del Pulgar EM, Cerrudo V, Sanz Y (2017) Gut microbiota, diet, and obesity-related disorders-The good, the bad, and the future challenges. Mol Nutr Food Res 61(1):1600252
75.
Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031PubMedCrossRef
76.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444:1022–1023PubMedCrossRef
77.
Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI (2009) A core gut microbiome in obese and lean twins. Nature 457:480–484PubMedCrossRef
78.
Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1:6ra14PubMedPubMedCentralCrossRef
79.
Blustein J, Attina T, Liu M, Ryan AM, Cox LM, Blaser MJ, Trasande L (2013) Association of caesarean delivery with child adiposity from age 6 weeks to 15 years. Int J Obes 37:900–906CrossRef
80.
Bergström A, Skov TH, Bahl MI, Roager HM, Christensen LB, Ejlerskov KT, Mølgaard C, Michaelsen KF, Licht TR (2014) Establishment of intestinal microbiota during early life: a longitudinal, explorative study of a large cohort of Danish infants. Appl Environ Microbiol 80:2889–2900PubMedPubMedCentralCrossRef
81.
Graff M, Ngwa JS, Workalemahu T, Homuth G, Schipf S, Teumer A, Völzke H, Wallaschofski H, Abecasis GR, Edward L, Francesco C, Sanna S, Scheet P, Schlessinger D, Sidore C, Xiao X, Wang Z, Chanock SJ, Jacobs KB, Hayes RB, Hu F, Van Dam RM; GIANT Consortium, Crout RJ, Marazita ML, Shaffer JR, Atwood LD, Fox CS, Heard-Costa NL, White C, Choh AC, Czerwinski SA, Demerath EW, Dyer TD, Towne B, Amin N, Oostra BA, Van Duijn CM, Zillikens MC, Esko T, Nelis M, Nikopensius T, Metspalu A, Strachan DP, Monda K, Qi L, North KE, Cupples LA, Gordon-Larsen P, Berndt SI (2013) Genome-wide analysis of BMI in adolescents and young adults reveals additional insight into the effects of genetic loci over the life course. Hum Mol Genet 22:3597–3607CrossRef
82.
Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. Sci 341:1241214CrossRef
83.
Trasande L, Blustein J, Liu M, Corwin E, Cox LM, Blaser MJ (2013) Infant antibiotic exposures and early-life body mass. Int J Obes 37:16–23CrossRef
84.
Muscogiuri G, Cantone E, Cassarano S, Tuccinardi D, Barrea L, Savastano S, Colao A (2019) on behalf of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Gut microbiota: a new path to treat obesity. Int J Obes Suppl 9(1):10–19PubMedPubMedCentralCrossRef
85.
Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, Hammer RE, Williams SC, Crowley J, Yanagisawa M, Gordon JI (2008) Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A 105:16767–16772PubMedPubMedCentralCrossRef
86.
Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, Hardt PD (2010) Microbiota and SCFA in lean and overweight healthy subjects. Obesity 18(1):190–195PubMedCrossRef
87.
Sowah SA, Riedl L, Damms-Machado A, Johnson TS, Schübel R, Graf M, Kartal E, Zeller G, Schwingshackl L, Stangl GI, Kaaks R, Kühn T (2019) Effects of weight-loss interventions on short-chain fatty acid concentrations in blood and feces of adults: a systematic review. Adv Nutr 10(4):673–684PubMedPubMedCentralCrossRef
88.
Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:1282–1286PubMedPubMedCentralCrossRef
89.
Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D, Hirano K, Tani T, Takahashi T, Miyauchi S, Shioi G, Inoue H, Tsujimoto G (2013) The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 4:1829PubMedCrossRef
90.
Chambers ES, Viardot A, Psichas A, Morrison DJ, Murphy KG, ZacVarghese SE, MacDougall K, Preston T, Tedford C, Finlayson GS et al (2015) Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64(11):1744–1754PubMedCrossRef
91.
Zeng H, Umar S, Rust B, Lazarova D, Bordonaro M (2019) Secondary bile acids and short chain fatty acids in the colon: a focus on colonic microbiome, cell proliferation, inflammation, and cancer. Int J Mol Sci 20(5):1214PubMedPubMedCentralCrossRef
92.
Sell H, Eckel J (2010) Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care 13:366–370PubMedCrossRef
93.
94.
Bleau C, Karelis AD, St-Pierre DH, Lamontagne L (2015) Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low grade inflammation and the development of obesity and diabetes. Diabetes Metab Res Rev 31:545–561PubMedCrossRef
95.
Gangarapu V, Yıldız K, Ince AT, Baysal B (2014) Role of gut microbiota: obesity and NAFLD. Turk J Gastroenterol 25:133–140PubMedCrossRef
96.
Moran CP, Shanahan F (2014) Gut microbiota and obesity: role in aetiology and potential therapeutic target. Best Pract Res Clin Gastroenterol 28:585–597PubMedCrossRef
97.
Remely M, Aumueller E, Jahn D, Hippe B, Brath H, Haslberger AG (2014) Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity. Benef Microbes 5:33–43PubMedCrossRef
98.
Shen J, Obin MS, Zhao L (2013) The gut microbiota, obesity and insulin resistance. Mol Aspects Med 34:39–58PubMedCrossRef
99.
Kim KA, Gu W, Lee IA, Joh EH, Kim DH (2012) High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One 7:e47713PubMedPubMedCentralCrossRef
100.
Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araújo EP, Vassallo J, Curi R, Velloso LA, Saad MJ (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56:1986–1998PubMedCrossRef
101.
Song MJ, Kim KH, Yoon JM, Kim JB (2006) Activation of toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 346:739–745PubMedCrossRef
102.
Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M (2004) Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 101:10679–10684PubMedPubMedCentralCrossRef
103.
Magouliotis DE, Tasiopoulou VS, Sioka E, Chatedaki C, Zacharoulis D (2017) Impact of bariatric surgery on metabolic and gut microbiota profile: a systematic review and meta-analysis. Obes Surg 27:1345–1357PubMedCrossRef
104.
Guo Y, Huang ZP, Liu CQ, Qi L, Sheng Y, Zou DJ (2018) Modulation of the gut microbiome: a systematic review of the effect of bariatric surgery. Eur J Endocrinol 178:43–56PubMedCrossRef
105.
Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R (2009) Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 106:2365–2370PubMedPubMedCentralCrossRef
106.
Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Doré J, Henegar C, Rizkalla S, Clément K (2010) Differential adaptation of human gut microbiota to bariatric surgery- induced weight loss: links with metabolic and low- grade inflammation markers. Diabetes 59:3049–3057PubMedPubMedCentralCrossRef
107.
Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, Li Y, Brach T, Liang S, Feng Q, Jørgensen NB, Bojsen-Møller KN, Dirksen C, Burgdorf KS, Holst JJ, Madsbad S, Wang J, Pedersen O, Hansen T, Arumugam M (2016) Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Med 8:67PubMedPubMedCentralCrossRef
108.
Tremaroli V, Karlsson F, Werling M, Ståhlman M, Kovatcheva-Datchary P, Olbers T, Fändriks L, le Roux CW, Nielsen J, Bäckhed F (2015) Roux- en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab 22:228–238PubMedPubMedCentralCrossRef
109.
Debédat J, Clément K, Aron-Wisnewsky J (2019) Gut microbiota dysbiosis in human obesity: impact of bariatric surgery. Curr Obes Rep 8(3):229–242PubMedCrossRef
110.
Aron-Wisnewsky J, Doré J, Clement K (2012) The importance of the gut microbiota after bariatric surgery. Nat Rev Gastroenterol Hepatol 9:590–598PubMedCrossRef
111.
Furet JP et al (2010) Differential adaptation of human gut microbiota to bariatric surgery induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59:3049–3057PubMedPubMedCentralCrossRef
112.
Murphy R et al (2017) Differential changes in gut microbiota after gastric bypass and sleeve gastrectomy bariatric surgery vary according to diabetes remission. Obes Surg 27:917–925PubMedCrossRef
113.
Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, Bloom SR, Darzi A, Athanasiou T, Marchesi JR, Nicholson JK, Holmes E (2011) Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 60:1214–1223PubMedCrossRef
114.
Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC (2016) Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 1:56–67PubMedCrossRef
115.
Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, Bekker JHR, Ghatei MA, Bloom SR, Walters JRF et al (2012) The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinol 153:3613–3619CrossRef
116.
Seyfried F, Phetcharaburanin J, Glymenaki M, Nordbeck A, Hankir M, Nicholson JK, Holmes E, Marchesi JR, Li JV (2021) Roux-en-Y gastric bypass surgery in Zucker rats induces bacterial and systemic metabolic changes independent of caloric restriction-induced weight loss. Gut Microbes 13:1–20PubMedCrossRef
117.
Koulas SG, Stefanou CK, Stefanou SK, Tepelenis K, Zikos N, Tepetes K, Kapsoritakis A (2021) Gut microbiota in patients with morbid obesity before and after bariatric surgery: a ten-year review study (2009–2019). Obes Surg 31:317–326PubMedCrossRef
118.
Ilhan Z, DiBaise JK, Dautel SE, Isern NG, Kim Y, Hoyt DW, Schepmoes AA, Brewer HM, Weitz KK, Metz TO et al (2020) Temporospatial shifts in the human gut microbiome and metabolome after gastric bypass surgery. NPJ Biofilms Microbiomes 6(1):12PubMedPubMedCentralCrossRef
119.
Talavera-Urquijo E, Beisani M, Balibrea JM, Alverdy JC (2020) Is bariatric surgery resolving NAFLD via microbiota-mediated bile acid ratio reversal? A comprehensive review. Surg Obes Relat Dis 16:1361–1369
120.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA (2011) Prevalence of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterol 140:124–131CrossRef
121.
Paquissi FC (2016) Immune imbalances in non-alcoholic fatty liver disease: from general biomarkers and neutrophils to interleukin-17 axis activation and new therapeutic targets. Front Immunol 7:490PubMedPubMedCentralCrossRef
122.
Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomilnson JW (2016) Non-alcoholic fatty liver disease and diabetes. Metab 65:1096–1108CrossRef
123.
Forlani G, Giorda C, Manti R, Mazzella N, De Cosmo S, Rossi MC, Nicolucci A, Di Bartolo P, Ceriello A, Guida P; AMD-Annals Study Group (2016) The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes. J Diabetes Res 2016:2931985
124.
Calle EE, Rodriguez C, Walker- Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedCrossRef
125.
Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K (2020) Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 17:279–297PubMedCrossRef
126.
Chen J, Vitetta L (2020) Letter to the Editor: Could butyrate be incorporated with Farnesoid X receptor agonist cilofexor to enhance primary sclerosing cholangitis treatment? Hepatol 72:1497–1498CrossRef
127.
Chen J, Vitetta L (2020) Butyrate in inflammatory bowel disease therapy. Gastroenterol 158:1511CrossRef
128.
129.
Sohail MU, Althani A, Anwar H, Rizzi R, Marei HE (2017) Role of the gastrointestinal tract microbiome in the pathophysiology of diabetes mellitus. J Diabetes Res 2017:9631435PubMedPubMedCentralCrossRef
130.
Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I (2021) Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health 40:50–58PubMedCrossRef
131.
Nseir W, Artul S, Nasrallah N, Mahamid M (2016) The association between primary bacteremia of presumed gastrointestinal origin and nonalcoholic fatty liver disease. Dig Liver Dis 48:343–344PubMedCrossRef
132.
Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E (2019) The role of the microbiome in NAFLD and NASH. EMBO Mol Med 11:e9302
133.
Chen J, Thomsen M, Vitetta L (2019) Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem 120:2713–2720PubMedCrossRef
134.
Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P (2015) Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterol 149:379–88CrossRef
135.
Bell LN, Temm CJ, Saxena R, Vuppalanchi R, Schauer P, Rabinovitz M, Krasinskas A, Chalasani N, Mattar SG (2010) Bariatric surgery- induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg 251:1041–1048PubMedCrossRef
136.
Karcz WK, Krawczykowski D, Kuesters S, Marjanovic G, Kulemann B, Grobe H, Karcz-Socha I, Hopt UT, Bukhari W, Grueneberger JM (2011) Influence of sleeve gastrectomy on NASH and type 2 diabetes mellitus. J Obes 2011:765473PubMedCrossRef
137.
Billeter AT, Senft J, Gotthardt D, Knefeli P, Nickel F, Schulte T, Fischer L, Nawroth PP, Büchler MW, Müller-Stich BP (2016) Combined non-alcoholic fatty liver disease and type 2 diabetes mellitus: sleeve gastrectomy or gastric bypass? A controlled matched pair study of 34 patients. Obes Surg 26:1867–1874PubMedCrossRef
138.
Algooneh A, Almazeedi S, Al-Sabah S, Ahmed M, Othman F (2016) Nonalcoholic fatty liver disease resolution following sleeve gastrectomy. Surg Endosc 30:1983–1987PubMedCrossRef
139.
Praveen Raj P, Gomes RM, Kumar S, Senthilnathan P, Karthikeyan P, Shankar A, Palanivelu C (2015) The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: “NASHOST” prospective observational trial. Surg Obes Relat Dis 11:1315–1322PubMedCrossRef
140.
Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH (2005) Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 13:1180–1186PubMedCrossRef
141.
Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA (2006) Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 101:368–373PubMedCrossRef
142.
Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA (2007) Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg 17:486–492PubMedCrossRef
143.
Furuya CK Jr, de Oliveira CP, de Mello ES, Faintuch J, Raskovski A, Matsuda M, Vezozzo DC, Halpern A, Garrido AB Jr, Alves VA et al (2007) Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 22:510–514PubMedCrossRef
144.
Froylich D, Corcelles R, Daigle C, Boules M, Brethauer S, Schauer P (2016) Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis 12:127–131PubMedCrossRef
145.
Kalinowski P, Paluszkiewicz R, Wróblewski T, Remiszewski P, Grodzicki M, Bartoszewicz Z, Krawczyk M (2017) Ghrelin, leptin, and glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass—results of a randomized clinical trial. Surg Obes Relat Dis 13:181–188PubMedCrossRef
146.
Le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108–114PubMedPubMedCentralCrossRef
147.
Musso G, Gambino R, Cassader M (2011) Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med 62:361–380PubMedCrossRef
148.
Cordeiro L, Campos JM, de Paula PS, Vilar L, Lopes E, de Arruda PC, Ramos A, Ferraz Á (2013) Nonalcoholic steatohepatitis on preoperative period of gastric bypass: lack of correlation with degree of obesity. ABCD Arq Bras Cir Dig 26(Suppl. 1):39–42PubMedCrossRef
Metadata
Title
Mechanisms linking bariatric surgery to adipose tissue, glucose metabolism, fatty liver disease and gut microbiota
Authors
Saverio Latteri
Maria Sofia
Stefano Puleo
Angelica Di Vincenzo
Saverio Cinti
Sergio Castorina
Publication date
01-12-2023
Publisher
Springer Berlin Heidelberg
Published in
Langenbeck's Archives of Surgery / Issue 1/2023
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-023-02821-8

Other articles of this Issue 1/2023

Langenbeck's Archives of Surgery 1/2023 Go to the issue

Correspondence

Long-term patient-focussed outcomes remain under-evaluated in reviews of pyloric drainage procedures in oesophagectomy

Brief Report

Converting a probe-based fluorescence system into an easy-to-use adjunct for the detection of parathyroid glands accidentally resected intraoperatively

Research

The effect of the enhanced recovery programme on long-term survival following liver resection for colorectal liver metastases

Original Article

Early laparoscopic cholecystectomy for acute cholecystitis: should we operate beyond the first week?

Brief Report

The “Tube Submarine Technique”: a safe and easy technique to place an external drainage tube during hepaticojejunostomy in minimally invasive surgery

Research

Multi-visceral resection for left-sided pancreatic ductal adenocarcinoma: a multicenter retrospective analysis from European countries